Literature DB >> 17101287

The oncogenic potential of growth hormone.

Jo K Perry1, B Starling Emerald, Hichem C Mertani, Peter E Lobie.   

Abstract

A growing body of recent literature indicates that in addition to an essential role in growth and development, growth hormone may also play a more sinister role in oncogenic transformation and neoplastic progression. Here we review the accumulating evidence implicating growth hormone in the development and progression of cancer and describe what is known of the mechanisms utilised by this hormone in neoplastic transformation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17101287     DOI： 10.1016/j.ghir.2006.09.006

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN： 1096-6374            Impact factor:   2.372


  40 in total

Review 1.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 2.  Gene doping: the hype and the reality.

Authors:  D J Wells
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

3.  Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Authors:  M Victoria Recouvreux; J Boyang Wu; Allen C Gao; Svetlana Zonis; Vera Chesnokova; Neil Bhowmick; Leland W Chung; Shlomo Melmed
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

4.  Lactogens and estrogens in breast cancer chemoresistance.

Authors:  Gila Idelman; Eric M Jacobson; Traci R Tuttle; Nira Ben-Jonathan
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

5.  A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important.

Authors:  Feng Liu; Leona Bessonova; Thomas H Taylor; Argyrios Ziogas; Frank L Meyskens; Hoda Anton-Culver
Journal:  Pigment Cell Melanoma Res       Date:  2012-11-21       Impact factor: 4.693

6.  Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells.

Authors:  Vijay Pandey; Jo K Perry; Kumarasamypet M Mohankumar; Xiang-Jun Kong; Shu-Min Liu; Zheng-Sheng Wu; Murray D Mitchell; Tao Zhu; Peter E Lobie
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 7.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

8.  Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.

Authors:  Johanna G Miquet; Thomas Freund; Carolina S Martinez; Lorena González; María E Díaz; Giannina P Micucci; Elsa Zotta; Ravneet K Boparai; Andrzej Bartke; Daniel Turyn; Ana I Sotelo
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

Review 9.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

10.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.